Страна: Армения
Язык: английский
Источник: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
linezolid
Liqvor CJSC
J01XX08
linezolid
2mg/ml
solution for infusion
plastic pack 300ml
Prescription
Registered
2021-05-21
1 PACKAGE LEAFLET: INFORMATION FOR THE USER LINEZOLID INJECTION SOLUTION FOR INFUSION 600 MG/300 ML READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects, including those not listed in section 4 of this leaflet. WHAT IS IN THIS LEAFLET 1. What LINEZOLID injection is and what it is used for. 2. What you need to know before you are treated with LINEZOLID injection. 3. How to use LINEZOLID injection. 4. Possible side effects. 5. How to store LINEZOLID injection. 6. Contents of the pack and other information 1. WHAT LINEZOLID INJECTION IS AND WHAT IT IS USED FOR LINEZOLID injection is an antibacterial drug of oxazolidinones group. It stops the growth of certain bacteria (microbes) that cause infectious diseases. Linezolid is used for the treatment of nosocomial and community-acquired pneumonia, complicated skin and skin structure infections (including diabetic foot infections, without concomitant osteomyelitis), vancomycin-resistant _ _ _Enterococcus _ _faecium _ infections, including cases with concurrent bacteremia. Your doctor will decide if LINEZOLID injection is suitable for the treatment of your infectious disease. 2 2. WHAT YOU NEED TO KNOW BEFORE YOU ARE TREATED WITH LINEZOLID INJECTION DO NOT TAKE LINEZOLID INJECTION IF: • you are allergic to linezolid or any of the other ingredients of this medicine (listed in section 6 of this leaflet). • you are taking or have taken within the last 2 weeks monoamine oxidase inhibitors (for example, phenelzine, isocarboxazid). These medicines may be used to treat depression or Parkinson’s disease. • you have uncontrolle Прочитать полный документ
( ) 1. , 600 /300 2. 2 6.1 : 3. : 4. 4.1 - , , , . _ _ _Staphylococcus _ _aureus_ _Streptococcus Pneumoniae _ , Streptococcus pneumonia ( _Staphylococcus _ _aureus_ , _ _ _ Staphylococcus aureus_ _) Streptococcus pyogenes _ _ Streptococcus _ _agalactiae_ ,_ _ , , _ Enterococcus faecium_ : _ _ 4.2. ( ) : 30-120 : : , : , , 100% : , , : * , (12 ) ( ** 11 ) 600 12 10 / 8 10-14 , , , _ _ _Enterococcus _ _faecium_ _ _ 600 12 10 / 8 14-28 ** . - . _ _ - _ _ _ _ 4.3. / 6.1 , A B ( , ) , 2 : , , , , , , , ( , , ), ( , ), ( ), , , 5- 1 ( ), , : 4.4 , , : : _ _ _ _ _ _ _ _ , : _ _ _ _ _ _ ( 2 ) , , , : : : , . , , / , , 2 : , : , : : , : , 28 : : _ _ _ _ _ _ _ _ , 28 , ( ) : 28 ( ) : : ( , , , ) : (28 ) , : : : _ _ _ _ , ( , ) : ( 4.3 ), : ( , ( ), ) : : _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ [78/363 (21,5%)] / / [58/363 (16,0%) : : ( 0,96; 95% . 0,58-1,59), (p=0,0162) , ( 2,48; 95% . 1,38-4,46): ` 7 : : , ( 4.1 ): : : _ _ _ _ _ _ _ _ _ _ _ _ , :_ _ _Clostridium difficile _ , : : , _ Clostridium difficile-_ : A B , : , _Clostridium _ _difficile _ : , : , : : _Clostridium _ _difficile _ 2 : _ _ : , , - : _ _ , : : _ _ _ _ _ _ _ _ _ (_ _)_ : , : / : _ _ _ _ _ _ , , ( ), , 28 : _ _ _ _ _ _ _ _ ( , , , ) : _ _ _ _ _ _ _ _ : : _ _ : : , 3%- : : 28 : « » , , : , : _ _ _ _ 300 (1 ) 51,9 (1194 ) , : 4.5 _In vitro _ : D6, : , CYP450- : CYP2C9 (S)- : CYP2C9 , , : (Cmax) (AUC) 21 %- 32 %- : : , , : : , . ( , , , , ), ( ): : ( ) : , ( ) : 4.6. _ _ : , : _ _ _ _ _ _ : : , : 4.7. : , : 4.8 . <1/1000), (<1/10000), ( ): : (8,3%), (5,7%), (6,6%), (4,3%): _ _ _ _ _ _ . ( , ), , ( ), , *: _ _ _ _ _ _ _ _ . * ǂ , *, , *, , *, *, *: _ _ _ _ . : _ _ _ _ _ _ _._ , *: _ _ . : _ _ _ _ _._ , ( « » ), , *, , , **, *: _ _ _ _ _ _ _._ *, *, *, *, *, *, *: _ _ _ _ _ _ _ _ _._ : _-_ _ _ . , ( ), , , : _-_ _ _ _._ , , , , , , , , , , , , , , : _-_ _ _ _. _ , , , , , : _ _ _ _ _ _ _ _ Прочитать полный документ